KYAN 001
Alternative Names: KYAN-001Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Georgetown University
- Developer KYAN Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action HDAC4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in Singapore
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 25 Sep 2020 KYAN Therapeutics and Georgetown University entered a licensing agreement for the development of KYAN 001